Cat. #161932
SH-SY5Y Cell Line
Cat. #: 161932
Availability: 8-10 weeks
Tissue: Bone, Marrow tissue
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: June L. Biedler, Barbara A. Spengler
Institute: Memorial Sloan-Kettering Cancer (MSK)
Primary Citation: Ross et al. 1983. Journal of the National Cancer Institute. 71(4):741-7. PMID: 6137586.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: SH-SY5Y Cell Line
- Cancer: Neurological cancer
- Cancers detailed: Neuroblastoma
- Gender: Female
- Tissue: Bone, Marrow tissue
- Morphology: Epithelial
- Growth properties: Mixed: adherent and suspension
- Products or characteristics of interest: Karyotype: Modal number = 47; the cells possess a unique marker comprised of a chromosome 1 with a complex insertion of an additional copy of a 1q segment into the long arm, resulting in trisomy of 1q
- Description: SH-SY5Y is a thrice-subcloned cell line derived from the SK-N-SH neuroblastoma cell line.
- Application: 3D cell culture; High-throughput screening; Immunology; Neuroscience; Toxicology
- Biosafety level: 1
- Additional notes: SH-SY5Y cells have a reported saturation density greater than 1 X 106 cells/cm2. They are reported to exhibit moderate levels of dopamine beta hydroxylase activity.
Target Details
- Target: Antigen expression: Blood Type A; Rh+
Applications
- Application: 3D cell culture; High-throughput screening; Immunology; Neuroscience; Toxicology
Handling
- Growth medium: 1:1 mixture of ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003, and F12 Medium then supplemented with fetal bovine serum to a final concentration of 10%.
- Temperature: 37° C
- Atmosphere: 5% CO2 in air
- Shipping conditions: Dry Ice
- Storage medium: Complete growth medium supplemented with 5% DMSO
- Str profiling: Amelogenin: XCSF1PO: 11D13S317: 11D16S539: 8,13D5S818: 12D7S820: 7,10TH01: 7,10TPOX: 8,11vWA: 14,18D3S1358: 15,16D21S11: 31,31.2D18S51: 13,16Penta_E: 7,11Penta_D: 10,12D8S1179: 15FGA: 23.2,24D19S433: 13,14D2S1338: 17,19
References
- Zanker et al. 2023. Frontiers in molecular neuroscience. 16:1280556. PMID: 38098942.
- Thirant et al. 2023. Nature communications. 14(1):2575. PMID: 37142597.
